Close Menu

AlCana Technologies

Alnylam Pharmaceuticals researchers last month published details on the company’s efforts to improve lipid nanoparticles for RNAi drug delivery.

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

Tekmira Pharmaceuticals' CEO this week provided an update on the company's ongoing litigation with partner Alnylam Pharmaceuticals, confirming that a roughly one-year-old technology-misappropriation lawsuit could be resolved before the end of 2012.

Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Tekmira Pharmaceuticals this week announced that it has filed a notice of civil claim in the Supreme Court of British Columbia alleging that “certain individuals” from AlCana Technologies wrongly took “thousands of confidential documents” containing Tekmira information and trade

By Doug Macron
AlCana Technologies last month denied that its researchers violated non-compete agreements with their former employer, Tekmira Pharmaceuticals, as part of a legal claim filed against it by that company.

Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.